Bulletin
Investor Alert

New York Markets Open in:

Dicerna Pharmaceuticals Inc.

NAS: DRNA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 20, 2021, 4:06 p.m.

/zigman2/quotes/203776010/composite

$

20.77

Change

0.00 0.00%

Volume

Volume 19,409

Quotes are delayed by 20 min

/zigman2/quotes/203776010/composite

Previous close

$ 20.87

$ 20.77

Change

-0.10 -0.48%

Day low

Day high

$20.50

$21.00

Open

52 week low

52 week high

$18.96

$40.14

Open

Company Description

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalX...

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Valuation

Price to Sales Ratio

9.95

Price to Book Ratio

12.12

Price to Cash Flow Ratio

8.81

Enterprise Value to Sales

6.80

Total Debt to Enterprise Value

0.05

Efficiency

Revenue/Employee

544,063.00

Income Per Employee

-373,334.00

Receivables Turnover

1.39

Total Asset Turnover

0.25

Liquidity

Current Ratio

3.48

Quick Ratio

3.48

Cash Ratio

3.20

Profitability

Operating Margin

-68.90

Pretax Margin

-68.62

Net Margin

-68.62

Return on Assets

-17.03

Return on Equity

-77.77

Return on Total Capital

-61.92

Return on Invested Capital

-62.84

Capital Structure

Total Debt to Total Equity

37.88

Total Debt to Total Capital

27.47

Total Debt to Total Assets

7.18

Long-Term Debt to Equity

35.38

Long-Term Debt to Total Capital

25.66

Officers and Executives

Name Age Officer Since Title
Dr. Douglas M. Fambrough 51 2007 Director
Mr. James B. Weissman 58 2012 Chief Operating Officer & Executive Vice President
Mr. Douglas W. Pagán 48 2020 Chief Financial Officer
Dr. Shreeram Aradhye 57 2020 Chief Medical Officer & Executive Vice President
Dr. Bob D. Brown 55 2008 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/17/2021 Shreeram Aradhye
EVP & Chief Medical Officer
2,056   Disposition at $21.47 per share. 44,142
09/17/2021 Ling Zeng
Chief Legal Officer & Sec y
1,334   Disposition at $21.47 per share. 28,640
09/17/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
21,250   Disposition at $21.06 per share. 447,525
09/15/2021 Shreeram Aradhye
EVP & Chief Medical Officer
7,025   Derivative/Non-derivative trans. at $0 per share. 0
09/15/2021 Ling Zeng
Chief Legal Officer & Sec y
4,556   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Douglas M. Fambrough
President and CEO; Director
5,000   Acquisition at $22.1 per share. 110,500
08/10/2021 Marc D. Kozin
Director
3,000   Acquisition at $23.66 per share. 70,980
08/02/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
8,312   Disposition at $37.38 per share. 310,702
08/02/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
8,312   Derivative/Non-derivative trans. at $3.42 per share. 28,427
07/06/2021 James B. Weissman
Chief Operating Officer & EVP
30,000   Disposition at $39.09 per share. 1,172,700
07/06/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,404   Derivative/Non-derivative trans. at $37.05 per share. 52,018
07/06/2021 James B. Weissman
Chief Operating Officer & EVP
30,000   Derivative/Non-derivative trans. at $9.09 per share. 272,700
07/06/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,712   Derivative/Non-derivative trans. at $0 per share. 0
07/06/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,450   Derivative/Non-derivative trans. at $0 per share. 0
07/01/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
1,066   Disposition at $37.85 per share. 40,348
07/01/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
7,246   Disposition at $37.3 per share. 270,275
07/01/2021 Bob D. Brown
Chief Scientific Ofr., EVP R&D
8,312   Derivative/Non-derivative trans. at $3.42 per share. 28,427
06/25/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,000   Disposition at $38 per share. 38,000
06/25/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,000   Derivative/Non-derivative trans. at $22.58 per share. 22,580
06/22/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
4,880   Disposition at $36.71 per share. 179,144
06/22/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
13,555   Disposition at $37.1 per share. 502,890
06/22/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
2,406   Derivative/Non-derivative trans. at $24.05 per share. 57,864
06/22/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
2,279   Derivative/Non-derivative trans. at $22.58 per share. 51,459
06/22/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
13,750   Derivative/Non-derivative trans. at $12.93 per share. 177,787
06/17/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
8,664   Disposition at $35.79 per share. 310,084
06/17/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
4,000   Derivative/Non-derivative trans. at $24.05 per share. 96,200
06/17/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
4,664   Derivative/Non-derivative trans. at $12.93 per share. 60,305
06/16/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
100   Disposition at $36.15 per share. 3,615
06/16/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
31,464   Disposition at $35.63 per share. 1,121,062
06/16/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
1,564   Derivative/Non-derivative trans. at $26.62 per share. 41,633
06/16/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
10,000   Derivative/Non-derivative trans. at $22.58 per share. 225,800
06/16/2021 Regina M. DeTore Paglia
Chief Human Resources Officer
20,000   Derivative/Non-derivative trans. at $12.93 per share. 258,600
/news/latest/company/us/drna

MarketWatch News on DRNA

  1. Dicerna Pharmaceuticals stock price target raised to $49 from $40 at B. Riley

    7:47 a.m. June 25, 2021

    - Tomi Kilgore

  2. Vertex Slides After Surprise Halt to a Promising Drug Trial

    2:09 p.m. Oct. 15, 2020

    - Barron's Online

  3. Arrowhead Stock’s Surge Will Continue, Analyst Says

    10:53 a.m. Nov. 29, 2019

    - Barron's Online

  4. Viex Capital Takes a Dip in Immersion Corp.

    9:30 p.m. June 7, 2019

    - Barron's Online

  5. Dicerna Pharmaceuticals stock price target raised to $26 from $20 at SunTrust RH

    8:57 a.m. March 13, 2019

    - Tomi Kilgore

  6. Legion Partners Sees Untapped Value in OneSpan

    12:50 a.m. Nov. 10, 2018

    - Barron's Online

  7. Dicerna Pharmaceuticals stock price target raised to $21.00 from $13.50 at B. Riley FBR

    10:01 a.m. Nov. 6, 2018

    - Tomi Kilgore

  8. Dicerna Pharmaceuticals upgraded to buy from neutral at B. Riley FBR

    10:01 a.m. Nov. 6, 2018

    - Tomi Kilgore

  9. Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance

    7:49 a.m. Oct. 24, 2018

    - Emma Court

  10. Elliott Associates Likes Solid Service of Travelport

    8:53 p.m. March 30, 2018

    - Barron's Online

  11. Big Biotech Buys: Vericel, Achillion, PTC, Dicerna

    1:33 p.m. March 1, 2018

    - Barron's Online

  12. Dicerna Pharmaceuticals started at buy with $13 stock price target at SunTrust RH

    8:37 a.m. Feb. 5, 2018

    - Tomi Kilgore

  13. Lowe’s Is Adding Three New Directors to Board

    12:15 a.m. Jan. 27, 2018

    - Barron's Online

  14. Bain Makes Bank in Two Rebounding Biotechs

    8:58 a.m. Dec. 21, 2017

    - Barron's Online

/news/nonmarketwatch/company/us/drna

Other News on DRNA

  1. Here's Why Inhibrx Stock Is on the Move Today

    12:11 p.m. Oct. 12, 2021

    - Motley Fool

  2. Dicerna Pharmaceuticals announces several executive changes

    8:13 a.m. Sept. 22, 2021

    - Seeking Alpha

  3. Dicerna's PH2 Failure Changes Everything

    10:05 a.m. Aug. 22, 2021

    - Seeking Alpha

  4. 10-Q: DICERNA PHARMACEUTICALS INC

    7:08 a.m. Aug. 9, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. Dicerna Pharmaceuticals Q2 2021 Earnings Preview

    9:40 p.m. Aug. 8, 2021

    - Seeking Alpha

  6. Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

    2:43 p.m. Aug. 6, 2021

    - Motley Fool

  7. BTBT, TRUE, HCI among midday movers

    12:32 p.m. Aug. 6, 2021

    - Seeking Alpha

  8. Loading more headlines...

At a Glance

Dicerna Pharmaceuticals, Inc.

75 Hayden Avenue

Lexington, Massachusetts 02421

Phone

1 6176218097

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$164.31M

Net Income

$-112.75M

2020 Sales Growth

587.4%

Employees

302.00

/news/pressrelease/company/us/drna

Press Releases on DRNA

  1. Dicerna Announces New Executive Leadership Appointments

    7:30 a.m. Sept. 22, 2021

    - BusinessWire - BZX

  2. Dicerna to Participate in 16th Annual Citi Biopharma Conference

    4:05 p.m. Sept. 2, 2021

    - BusinessWire - BZX

  3. Royalty Pharma Reports Second Quarter 2021 Results

    7:00 a.m. Aug. 11, 2021

    - GlobeNewswire

  4. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.01%
  • /zigman2/quotes/200164174/composite SNOA+85.40%
  • /zigman2/quotes/202092269/composite ENSC+35.46%
  • /zigman2/quotes/226465160/composite ALF-14.72%
  • /zigman2/quotes/207732364/composite MSFT+1.66%
X
Powered by StockTwits
Link to MarketWatch's Slice.